DE60108754T2 - Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum - Google Patents
Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum Download PDFInfo
- Publication number
- DE60108754T2 DE60108754T2 DE60108754T DE60108754T DE60108754T2 DE 60108754 T2 DE60108754 T2 DE 60108754T2 DE 60108754 T DE60108754 T DE 60108754T DE 60108754 T DE60108754 T DE 60108754T DE 60108754 T2 DE60108754 T2 DE 60108754T2
- Authority
- DE
- Germany
- Prior art keywords
- yloxy
- methyl
- phenylamino
- pyridin
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 Cc1c[n](*)nc1 Chemical compound Cc1c[n](*)nc1 0.000 description 1
- VHWFNFITHSPBSR-UHFFFAOYSA-N Cc1c[o]nc1 Chemical compound Cc1c[o]nc1 VHWFNFITHSPBSR-UHFFFAOYSA-N 0.000 description 1
- YUTQRQJTFPEEPB-UHFFFAOYSA-N Cc1c[s]nc1 Chemical compound Cc1c[s]nc1 YUTQRQJTFPEEPB-UHFFFAOYSA-N 0.000 description 1
- TWGNOYAGHYUFFR-UHFFFAOYSA-N Cc1cncnc1 Chemical compound Cc1cncnc1 TWGNOYAGHYUFFR-UHFFFAOYSA-N 0.000 description 1
- AIKUBOPKWKZULG-UHFFFAOYSA-N Cc1cnncc1 Chemical compound Cc1cnncc1 AIKUBOPKWKZULG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21313600P | 2000-06-22 | 2000-06-22 | |
US213136P | 2000-06-22 | ||
PCT/IB2001/001046 WO2001098277A2 (en) | 2000-06-22 | 2001-06-14 | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60108754D1 DE60108754D1 (de) | 2005-03-10 |
DE60108754T2 true DE60108754T2 (de) | 2005-06-23 |
Family
ID=22793862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60108754T Expired - Lifetime DE60108754T2 (de) | 2000-06-22 | 2001-06-14 | Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum |
Country Status (43)
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7772432B2 (en) * | 1991-09-19 | 2010-08-10 | Astrazeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
NZ510210A (en) * | 1998-10-01 | 2003-06-30 | Astrazeneca Ab | 4-phenylamino substituted quinazoline or quinoline derivatives useful for treating cytokine mediated diseases or conditions |
PL359557A1 (en) * | 2000-06-22 | 2004-08-23 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
DE60237145D1 (de) * | 2001-02-21 | 2010-09-09 | Mitsubishi Tanabe Pharma Corp | Chinazolinderivate |
US20030144308A1 (en) * | 2001-09-24 | 2003-07-31 | Bauer Paul H. | Fructose 1,6-bisphosphatase inhibitors |
WO2003045939A1 (en) * | 2001-11-30 | 2003-06-05 | Pfizer Products Inc. | Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth |
MXPA04004107A (es) * | 2001-12-12 | 2004-07-23 | Pfizer Prod Inc | Moleculas pequenas para el tratamiento del crecimiento celular anormal. |
EP1456199A1 (en) | 2001-12-12 | 2004-09-15 | Pfizer Products Inc. | Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
EP1521747B1 (en) | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
US7488823B2 (en) * | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
EP1567506A4 (en) | 2002-11-20 | 2007-06-20 | Array Biopharma Inc | CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR |
AU2003303045A1 (en) * | 2002-12-18 | 2004-07-09 | Pfizer Products Inc. | 4-anilino quinazoline derivatives for the treatment of abnormal cell growth |
MXPA05006582A (es) * | 2002-12-19 | 2005-08-16 | Pfizer Prod Inc | Complejos de e-2-metoxi -n-(3 -{4-[3 -metil-4 -(6-metilpiridin -3- iloxi) fenilamino] quinazolin -6-il} alil) acetamida, su procedimiento de produccion y uso. |
RU2005125607A (ru) * | 2003-04-09 | 2006-03-27 | Пфайзер Продактс Инк. (Us) | Способы получения производных n(пиридинилокси)-фениламино)хиназолинил)аллил)ацетамида и родственных соединений, а также промежуточные соединения для таких способов и способы получения таких соединений |
JP2007501854A (ja) * | 2003-05-27 | 2007-02-01 | ファイザー・プロダクツ・インク | 受容体型チロシンキナーゼ阻害薬としてのキナゾリン類およびピリド[3,4−d]ピリミジン類 |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
CN1984660B (zh) * | 2003-07-03 | 2010-12-15 | 美瑞德生物工程公司 | 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉 |
EP1644017A2 (en) * | 2003-07-15 | 2006-04-12 | National Research Council Of Canada | Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells |
US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
PL1660090T3 (pl) * | 2003-08-14 | 2013-04-30 | Array Biopharma Inc | Analogi chinazoliny jako inhibitory kinaz tyrozynowych receptora |
MXPA06001989A (es) * | 2003-08-18 | 2006-05-17 | Pfizer Prod Inc | Programa de dosificacion para un nuevo agente anticanceroso. |
GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
SI2213661T1 (sl) * | 2003-09-26 | 2011-11-30 | Exelixis Inc | c-Met modulatorji in postopki uporabe |
BRPI0416190A (pt) * | 2003-11-06 | 2007-01-23 | Pfizer Prod Inc | combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro |
DE602005010824D1 (de) | 2004-02-03 | 2008-12-18 | Astrazeneca Ab | Chinazolinderivate |
US20050192298A1 (en) * | 2004-02-27 | 2005-09-01 | Pfizer Inc | Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide |
EP2335727A3 (en) | 2004-07-16 | 2011-09-28 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody |
WO2006025490A1 (ja) * | 2004-09-01 | 2006-03-09 | Mitsubishi Pharma Corporation | 分子シャペロン機能調節剤 |
KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
WO2006071079A1 (en) * | 2004-12-29 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
BRPI0608096A2 (pt) | 2005-04-26 | 2009-11-10 | Pfizer | anticorpos p-caderina |
CA2610491A1 (en) * | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Bicyclic derivatives for the treatment of abnormal cell growth |
JP2008542354A (ja) * | 2005-06-03 | 2008-11-27 | ファイザー・プロダクツ・インク | 癌治療におけるerbB2阻害剤と他の治療薬の併用 |
TWI370137B (en) | 2005-09-07 | 2012-08-11 | Amgen Fremont Inc | Human monoclonal antibodies to activin receptor-like kinase-1 |
JP5134548B2 (ja) | 2005-11-15 | 2013-01-30 | アレイ バイオファーマ、インコーポレイテッド | 過剰増殖性疾患の処置のためのErbBI型受容体チロシンキナーゼ阻害剤としてのN4−フェニルキナゾリン−4−アミン誘導体および関連化合物 |
GB0526552D0 (en) * | 2005-12-29 | 2006-02-08 | Morvus Technology Ltd | New use |
CN101490046A (zh) | 2006-05-09 | 2009-07-22 | 辉瑞产品公司 | 环烷基氨基酸衍生物及其药物组合物 |
WO2008002039A1 (en) * | 2006-06-28 | 2008-01-03 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting the growth of cancer cell |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
JP5580592B2 (ja) | 2006-09-11 | 2014-08-27 | キュリス,インコーポレイテッド | 亜鉛結合部分を含むキナゾリン系egfrインヒビター |
EP2061772A4 (en) * | 2006-09-11 | 2011-06-29 | Curis Inc | MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
BRPI0720169A2 (pt) | 2006-12-12 | 2013-12-24 | Takeda Pharmaceutical | Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto |
CA2677336A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof |
EP2076289B1 (en) | 2007-04-13 | 2014-11-12 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer resistant to erbb therapeutics |
US8497369B2 (en) | 2008-02-07 | 2013-07-30 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production |
US20090233937A1 (en) | 2008-03-12 | 2009-09-17 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
US8426430B2 (en) * | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
WO2010015522A1 (de) | 2008-08-08 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
US8877776B2 (en) | 2009-01-16 | 2014-11-04 | Exelixis, Inc. | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
EP2473500A2 (en) | 2009-09-01 | 2012-07-11 | Pfizer Inc. | Benzimidazole derivatives |
US9265739B2 (en) | 2010-06-02 | 2016-02-23 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to HER2/neu receptor complex |
WO2011153049A1 (en) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
JP5802756B2 (ja) | 2010-10-20 | 2015-11-04 | ファイザー・インク | スムーズンド受容体モジュレーターとしてのピリジン−2−誘導体 |
ES2575710T3 (es) | 2011-09-22 | 2016-06-30 | Pfizer Inc | Derivados de pirrolopirimidina y purina |
CN102872018B (zh) * | 2012-10-23 | 2015-07-15 | 广州市恒诺康医药科技有限公司 | 酪氨酸激酶不可逆抑制剂及其制备方法和用途 |
US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
AP2016009530A0 (en) | 2014-04-30 | 2016-10-31 | Pfizer | Cycloalkyl-linked diheterocycle derivatives |
KR101589632B1 (ko) | 2014-06-03 | 2016-02-01 | 한국과학기술연구원 | 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체 |
WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
US10287401B2 (en) | 2015-07-01 | 2019-05-14 | California Institute Of Technology | Cationic mucic acid polymer-based delivery systems |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
CN115057861A (zh) | 2016-03-01 | 2022-09-16 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
EP3806887A4 (en) | 2018-06-13 | 2022-04-06 | California Institute of Technology | NANOPARTICLES FOR CROSSING THE BLOOD-BRAIN BARRIER AND METHODS OF TREATMENT USING IT |
EP3853220B1 (en) | 2018-09-18 | 2024-01-03 | F. Hoffmann-La Roche AG | Quinazoline derivatives as antitumor agents |
WO2023185793A1 (zh) * | 2022-03-28 | 2023-10-05 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW321649B (US20070244113A1-20071018-C00087.png) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
JP2002527436A (ja) | 1998-10-08 | 2002-08-27 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
PL359557A1 (en) * | 2000-06-22 | 2004-08-23 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
-
2001
- 2001-06-14 PL PL01359557A patent/PL359557A1/xx not_active Application Discontinuation
- 2001-06-14 GE GE5023A patent/GEP20063831B/en unknown
- 2001-06-14 EP EP01938484A patent/EP1292591B1/en not_active Expired - Lifetime
- 2001-06-14 CN CN01811470A patent/CN1437594A/zh active Pending
- 2001-06-14 UA UA20021210405A patent/UA73990C2/uk unknown
- 2001-06-14 DZ DZ013407A patent/DZ3407A1/fr active
- 2001-06-14 AU AU2001264159A patent/AU2001264159A1/en not_active Abandoned
- 2001-06-14 DK DK01938484T patent/DK1292591T3/da active
- 2001-06-14 KR KR1020027017489A patent/KR100545537B1/ko not_active IP Right Cessation
- 2001-06-14 CZ CZ20023951A patent/CZ20023951A3/cs unknown
- 2001-06-14 EA EA200201277A patent/EA005525B1/ru not_active IP Right Cessation
- 2001-06-14 AP APAP/P/2001/002192A patent/AP2001002192A0/en unknown
- 2001-06-14 CA CA002413424A patent/CA2413424C/en not_active Expired - Fee Related
- 2001-06-14 CN CNA200810144110XA patent/CN101348467A/zh active Pending
- 2001-06-14 WO PCT/IB2001/001046 patent/WO2001098277A2/en active Application Filing
- 2001-06-14 DE DE60108754T patent/DE60108754T2/de not_active Expired - Lifetime
- 2001-06-14 IL IL15298501A patent/IL152985A0/xx unknown
- 2001-06-14 AT AT01938484T patent/ATE288431T1/de not_active IP Right Cessation
- 2001-06-14 JP JP2002504233A patent/JP4044839B2/ja not_active Expired - Fee Related
- 2001-06-14 BR BR0111548-0A patent/BR0111548A/pt not_active IP Right Cessation
- 2001-06-14 HU HU0301120A patent/HUP0301120A2/hu unknown
- 2001-06-14 MX MXPA02012870A patent/MXPA02012870A/es active IP Right Grant
- 2001-06-14 CN CNB2004100696071A patent/CN1330640C/zh not_active Expired - Fee Related
- 2001-06-14 YU YU95102A patent/YU95102A/sh unknown
- 2001-06-14 SK SK1710-2002A patent/SK17102002A3/sk unknown
- 2001-06-14 PT PT01938484T patent/PT1292591E/pt unknown
- 2001-06-14 OA OA1200200382A patent/OA12291A/en unknown
- 2001-06-14 EE EEP200200710A patent/EE200200710A/xx unknown
- 2001-06-14 NZ NZ522568A patent/NZ522568A/xx unknown
- 2001-06-14 ES ES01938484T patent/ES2236240T3/es not_active Expired - Lifetime
- 2001-06-18 US US09/883,752 patent/US6890924B2/en not_active Expired - Fee Related
- 2001-06-20 PE PE2001000598A patent/PE20020257A1/es not_active Application Discontinuation
- 2001-06-20 PA PA20018520301A patent/PA8520301A1/es unknown
- 2001-06-20 MY MYPI20012895 patent/MY127181A/en unknown
- 2001-06-20 AR ARP010102936A patent/AR032353A1/es unknown
- 2001-06-21 TN TNTNSN01091A patent/TNSN01091A1/fr unknown
- 2001-06-21 SV SV2001000504A patent/SV2002000504A/es not_active Application Discontinuation
-
2002
- 2002-11-12 BG BG107269A patent/BG107269A/bg unknown
- 2002-11-14 IS IS6616A patent/IS6616A/is unknown
- 2002-12-13 HR HR20021005A patent/HRP20021005A2/xx not_active Application Discontinuation
- 2002-12-13 EC EC2002004393A patent/ECSP024393A/es unknown
- 2002-12-16 MA MA26954A patent/MA26914A1/fr unknown
- 2002-12-18 ZA ZA200210231A patent/ZA200210231B/en unknown
- 2002-12-20 NO NO20026166A patent/NO20026166D0/no unknown
-
2005
- 2005-03-11 HK HK05102099A patent/HK1069576A1/xx not_active IP Right Cessation
- 2005-03-14 US US11/079,648 patent/US7332493B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60108754T2 (de) | Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum | |
DE69915027T2 (de) | Heteroaromatische bizyklische Verbindungen mit Antikrebswirkung | |
DE69935807T2 (de) | Substituierte bizyclische derivate verwendbar als antitumor mittel | |
US7585869B2 (en) | Substituted heterocylces for the treatment of abnormal cell growth | |
JP4551771B2 (ja) | 抗増殖剤として有効な新規ベンゾイミダゾール誘導体 | |
DE60025747T2 (de) | Neue benzimidazol derivate verwendbar als antiproliferative mittel | |
US20080194596A1 (en) | Therapeutic Combination Including a Selective Erbb2 Inhibitor | |
DE60223279T2 (de) | Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum | |
DE60212487T2 (de) | Bizyklisch substituierte 4-Aminopyridopyrimidinderivate | |
ZA200501353B (en) | Novel benzoimidazole derivatives useful as antiproliferative agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: OSI PHARMACEUTICALS, INC. (N.D.GES.D. STAATES , US Owner name: PFIZER INC. (N.D.GES.D. STAATES DELAWARE), NEW, US |